Breaking News Instant updates and real-time market news.

MNK

Mallinckrodt

$45.76

1.25 (2.81%)

, TWX

Time Warner

$99.30

-0.49 (-0.49%)

10:50
07/17/17
07/17
10:50
07/17/17
10:50

Einhorn's Greenlight exited Mallinckrodt short bet, Time Warner long

Greenlight Capital's quarterly letter, which was obtained by The Fly, communicates to investors in David Einhorn's fund that Greenlight exited "an unusually large number of positions" in the quarter. Among those, Greenlight said it exited its long positions in IAC (IAC), Time Warner (TWX), and Liberty Global (LBTYA). The firm also said that it had closed its "profitable short position" in Mallinckrodt (MNK). In the letter, Einhorn also discussed the firm's previously disclosed short call on Tesla (TSLA) and long position in General Motors (GM). The firm's five largest equity longs are AerCap (AER), Bayer, CONSOL Energy (CNX), GM and Mylan (MYL), the letter states.

MNK

Mallinckrodt

$45.76

1.25 (2.81%)

TWX

Time Warner

$99.30

-0.49 (-0.49%)

IAC

IAC

$105.36

-0.71 (-0.67%)

LBTYA

Liberty Global

$32.82

0.31 (0.95%)

AER

AerCap

$48.06

0.43 (0.90%)

BAYRY

Bayer

$129.37

0.4 (0.31%)

CNX

CONSOL

$15.97

0.195 (1.24%)

MYL

Mylan

$39.21

0.16 (0.41%)

  • 26

    Jul

  • 27

    Jul

  • 01

    Aug

  • 03

    Aug

  • 08

    Aug

  • 03

    Sep

  • 09

    Oct

MNK Mallinckrodt
$45.76

1.25 (2.81%)

06/29/17
UBSW
06/29/17
NO CHANGE
Target $70
UBSW
Buy
Mallinckrodt sum-of-the-parts still supports $70 price target, says UBS
UBS analyst Marc Goodman said his sum-of-the-parts valuation for Mallinckrodt still supports a $70 price target. The analyst said shares at current price remain attractive with the key overhang being the sustainability of Acthar from competition. Without competition, Goodman believes the shares are worth $100. He sees a favorable risk/reward as management has talked about a sense of urgency in getting the stock moving. Goodman reiterated his Buy rating and $70 price target on Mallinckrodt shares.
06/16/17
CANT
06/16/17
INITIATION
Target $52
CANT
Overweight
Mallinckrodt initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Mallinckrodt with an Overweight rating and $52 price target.
06/20/17
JEFF
06/20/17
NO CHANGE
Target $70
JEFF
Buy
Jefferies sees $60-$75 per share buyout range for Mallinckrodt
Amid speculation that Mallinckrodt is seeking strategic alternatives, Jefferies analyst Anthony Petrone explored leveraged buyout scenarios in order to gauge the feasibility of a sponsor-led transaction. His work shows that within a $60-$75 per share takeout range, sponsors can clear a 30% internal rate of return hurdle under "modest assumptions" with upside to 45%-plus when engineering scenarios are considered. The largest risks to the LBO assumptions are around stability in Acthar pricing and the competitive landscape, Petrone tells investors in a research note. The analyst keeps a Buy rating on Mallinckrodt with a $70 price target. The specialty pharmaceutical company closed yesterday up 5%, or $1.94, to $43.64.
06/21/17
WELS
06/21/17
NO CHANGE
WELS
Outperform
Wells doesn't see Mallinckrodt at significant risk of violating debt covenants
Wells Fargo analyst David Maris believes Mallinckrodt's debt and leverage "seem very manageable" and argues that investors "should not be overly concerned" about the company's potential to violate its debt covenants. In a note issued before the open, Maris characterized Mallinckrodt's covenants as "loose." He keeps an Outperform rating on Mallinckrodt shares.
TWX Time Warner
$99.30

-0.49 (-0.49%)

05/03/17
05/03/17
DOWNGRADE

Hold
Wunderlich downgrades Charter on valuation, sees some level of M&A priced in
As previously reported, Wunderlich analyst Matthew Harrigan downgraded Charter (CHTR) to Hold from Buy, citing valuation. He thinks that the current stock price imbeds some expectation for merger activity, apart from an eventual collapse of the Liberty Broadband (LBRDA) and Liberty Ventures (LVNTA) ownership structure, he tells investors. While a theoretical merger with Verizon (VZ) is "at least as strategically compelling" as AT&T's (T) deal for Time Warner (TWX), Harrigan thinks that price and regulatory hurdles could be difficult to overcome. He cut his price target on Charter to $350 from $360.
04/24/17
OPCO
04/24/17
NO CHANGE
OPCO
Sprint, DISH the only assets for sale, says Oppenheimer
Oppenheimer analyst Timothy Horan noted that wireless companies will be allowed to discuss M&A, and says he sees Sprint (S) and possibly DISH (DISH) as the only assets for sale. The analyst believes the most likely outcome is for consolidation around the four major wireless providers, something along the lines of Charter (CHTR)/Sprint, T-Mobile (TMUS)/Comcast (CMCSA; CMCSK), Verizon (VZ)/DISH, with AT&T's (T) position "fairly solidified" with DirectTV/Time Warner (TWX). Further, Horan suspects Sprint will be sold first, most likely to Charter, although T-Mobile is a possibility and could be the controlling company/management and likely paying a premium for Sprint.
04/20/17
04/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Amazon.com (AMZN) downgraded to Peer Perform from Outperform at Wolfe Research with analyst Scott Mushkin saying shares are approaching his price target and he expects increasing competition through year-end. 2. Time Warner (TWX) downgraded to Hold from Buy at Pivotal Research with analyst Brian Wieser saying shares are trading near the value of AT&T's (T) offering price. 3. Molson Coors (TAP) downgraded to Market Perform from Outperform at Cowen with analyst Vivien Azer citing expectations for persistent beer volume headwinds. The analyst believes alcohol consumption could be pressured for at least the next decade, partly due to increased cannabis use, and a contraction in the alcohol cycle. Azer said Molson is uniquely exposed to the increasingly vibrant and growing cannabis markets and notes there is an inverse relationship between cannabis use and alcohol consumption over time. 4. eBay (EBAY) downgraded to Neutral from Buy at Monness Crespi with analyst James Cakmak saying he sees insufficient upside to estimates to justify the lofty valuation. The analyst said the path to double-digit growth may be pushed out 2019 and limited potential to outperform topline expectations in 2017. Further, the analyst sees margin pressures from product mix towards StubHub and rising development spend for the backend, and limited opportunities for multiple expansion. 5. Ruth's Hospitality (RUTH) downgraded to Market Perform from Outperform at Raymond James with analyst Brian Vaccaro citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/20/17
PIVT
04/20/17
DOWNGRADE
PIVT
Hold
Time Warner downgraded to Hold from Buy at Pivotal Research
Pivotal Research analyst Brian Wieser downgraded Time Warner (TWX) to Hold saying shares are trading near the value of AT&T's (T) offering price.
IAC IAC
$105.36

-0.71 (-0.67%)

06/14/17
BOFA
06/14/17
NO CHANGE
Target $133
BOFA
Buy
IAC discounted valuation not sustainable, says BofA/Merrill
BofA/Merrill analyst Nat Schindler believes IAC shares remain undervalued and is trading at a discount to enterprise value based on its ownership in Match and implied cost value of Angie's stock. The analyst also said the company has a high cash balance available for acquisitions and other asset in the portfolio have potential for value creation. Schindler rates IAC a Buy with a $133 price target.
05/26/17
PIPR
05/26/17
NO CHANGE
Target $130
PIPR
Overweight
IAC price target raised to $130 from $111 at Piper Jaffray
Piper Jaffray analyst Samuel Kemp raised his price target for IAC to $130 saying the upcoming close of the Angie's List/ HomeAdvisor deal could put "upward pressure" on the shares. The analyst remains bullish on HomeAdvisor fundamentals and keeps an Overweight rating on IAC.
05/09/17
AGIS
05/09/17
NO CHANGE
Target $115
AGIS
Buy
IAC price target raised to $115 from $86 at Aegis
Aegis analyst Victor Anthony raised IAC's price target to $115 from $86 to reflect the "unlocked value" of the Angie's List Homeservices business. The analyst believes the combination of HomeAdvisor and Angie's List will accelerate the adoption of the home services market given management's strong understanding of the business, having driven 30% topline growth at HomeAdvisor in the domestic market for 9 consecutive quarters. Anthony rates IAC a Buy.
05/08/17
LEHM
05/08/17
NO CHANGE
Target $105
LEHM
Overweight
IAC price target raised to $105 from $96 at Barclays
Barclays analyst Ross Sandler raised his price target for IAC to $105 saying that around $99 per share, Vimeo, apps and the company's cash are not being fully valued. The analyst maintains an Overweight rating on IAC following the Q1 results.
LBTYA Liberty Global
$32.82

0.31 (0.95%)

06/16/17
UBSW
06/16/17
INITIATION
Target $31
UBSW
Neutral
Liberty Global initiated with a Neutral at UBS
UBS analyst Polo Tang started Liberty Global (LBTYA) with a Neutral rating and $31 price target. The analyst, while admitting the stock's risk/reward "is becoming more attractive," prefers to await a better entry point. Tang looked at potential M&A upside from a deal with Vodafone (VOD), and says upside is "potentially significant." He believes a combination with Vodafone could yield synergies of $12-$16 per Liberty Global share, but adds a deal "is not necessarily imminent."
01/23/17
01/23/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Liberty Global (LBTYA) resumed with an Equal Weight at Morgan Stanley. 2. BioMarin (BMRN) and Incyte (INCY) were initiated with an Outperform at Credit Suisse. 3. GrubHub (GRUB) initiated with a Hold at Craig-Hallum. 4. Molson Coors (TAP) initiated with a Neutral at Credit Suisse. 5. Achaogen (AKAO) initiated with a Buy at Guggenheim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/17
FBCO
05/24/17
DOWNGRADE
Target $30
FBCO
Neutral
Liberty Global downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Henrik Herbst downgraded Liberty Global to Neutral and lowered his price target for the shares to $30 from $42. After years of price increases, European broadband customers are starting to resist further raises, Herbst tells investors in a research note. The longer-term strategic outlook for cable in Europe is also slowly deteriorating, the analyst adds.
05/15/17
SBSH
05/15/17
NO CHANGE
Target $40
SBSH
Buy
Liberty Global pullback brings attractive entry point, says Citi
Citi analyst Simon Weeden views the post-earnings selloff in shares of Liberty Global as creating an attractive entry point. The analyst continues to see potential for "strong" free cash flow following the new build investment phase and for value creating M&A both as an acquirer and target. He keeps a Buy rating on Liberty Global with a $40 price target.
AER AerCap
$48.06

0.43 (0.90%)

04/06/17
MSCO
04/06/17
DOWNGRADE
MSCO
Equal Weight
AerCap downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani downgraded AerCap to Equal Weight and lowered his price target to $44 from $48 telling investors shares have had a solid run and faces headwinds from peaking airline profits and order activity.
01/04/17
COMP
01/04/17
INITIATION
Target $60
COMP
Buy
AerCap initiated with a Buy at Compass Point
Compass Point analyst Scott Valentin initiated AerCap with a Buy and a $60 price target.
01/04/17
COMP
01/04/17
INITIATION
Target $60
COMP
Buy
AerCap initiated with a Buy at Compass Point
Compass Point analyst Scott Valentin initiated AerCap with a Buy and a $60 price target. The analyst said AerCap has a high level of earnings visibility given the robust order book and high percentage of future deliveries placed, high level of profitability as evidenced by strong profit margin and relatively high ROE; and is best positioned among lessors to benefit from a reduction in the corporate tax rate.
05/22/17
DADA
05/22/17
NO CHANGE
DADA
AerCap shares should be bought at current levels, says DA Davidson
DA Davidson analyst Arren Cyganovich says that AerCap's stock has reached an attractive entry point. The analyst thinks that the company has "strong growth dynamics," while the stock's current valuation would be low even if the environment became "severely stressed." Cyganovich does not expect the latter scenario to unfold and keeps a $60 price target and Buy rating on the stock.
BAYRY Bayer
$129.37

0.4 (0.31%)

03/03/17
JPMS
03/03/17
NO CHANGE
Target $128
JPMS
Overweight
EU approvals of other ag deals may narrow Monsanto deal spread, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas said commentary from the CEOs of DuPont (DD) and Syngenta (SYT) and press reports from Europe suggest that their deals with Dow Chemical (DOW) and ChemChina, respectively, are likely to be approved. Approvals from Europe for those deals may "trigger a meaningful closing of the arbitrage spread" in Monsanto (MON) shares versus Bayer's (BAYRY) offer price, Zekauskas tells investors. He recommends buying Monsanto shares at current levels for this reason, adding that he believes the shares would only fall about 2.5%, or down to $112, in the event of the Bayer deal falling through. Zekauskas keeps an Overweight rating and $128 price target on Monsanto shares, which closed yesterday at just below $115 per share.
04/06/17
JPMS
04/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares offer 'excellent' risk/reward proposition, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says shares of Monsanto (MON) at current levels offer an "excellent" risk/reward proposition. The analyst views capital appreciation potential to the end of 2017 as 11% or a 15% annual return. He sees downside risk of only 3%, to $112 per share, in the event that Bayer (BAYRY) is not able to consummate the acquisition. Zekauskas has increased confidence in the deal closing following recent regulatory rulings and keeps an Overweight rating on the name with a $128 price target.
04/10/17
PIPR
04/10/17
NO CHANGE
Target $17
PIPR
Overweight
OncoMed price target lowered to $17 from $26 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for OncoMed (OMED) to $17 from $26 following two negative announcements, namely that the Phase II YOSEMITE study of demcizumab in first line pancreatic cancer failed and Bayer (BAYRY) returned rights for ipafricept and vantictumab. The analyst also notes that now partner Celgene (CELG) will review all data on demcizumab including Phase II DENALI non-small cell lung cancer data and Phase Ib combo data with KEYTRUDA, although he does not expect Celgene to exercise its option. Tenthoff reiterates an Overweight rating on OncoMed's shares.
06/27/17
SUSQ
06/27/17
DOWNGRADE
Target $128
SUSQ
Neutral
Monsanto downgraded to Neutral at Susquehanna
As previously reported, Susquehanna analyst Don Carson downgraded Monsanto (MON) to Neutral from Positive. The downgrade reflects the 9% upside to the $128 price target offer from Bayer (BAYRY), which is less than the firm's 15% threshold for a Positive rating. The companies expects the deal to close by calendar year-end 2017.
CNX CONSOL
$15.97

0.195 (1.24%)

12/09/16
GSCO
12/09/16
INITIATION
Target $21
GSCO
Neutral
CONSOL initiated with a Neutral at Goldman
Goldman analyst John Nelson initiated CONSOL with a Neutral and a $21 price target.
12/09/16
12/09/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chesapeake Utilities (CPK) initiated with a Neutral at Ladenburg. 2. CONSOL (CNX) initiated with a Neutral at Goldman. 3. Johnson Controls (JCI) assumed with an Equal Weight at Barclays. 4. American Midstream Partners (AMID) initiated with a Buy at Janney Capital. 5. Brookfield Infrastructure (BIP) coverage resumed with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/30/17
RHCO
01/30/17
DOWNGRADE
RHCO
Hold
CONSOL downgraded to Hold from Buy at SunTrust
01/30/17
01/30/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Colgate-Palmolive (CL) downgraded to Neutral from Buy at Citi with analyst Wendy Nicholson saying the sales the "breadth of the top-line weakness" in the company's fourth quarter results is "very disconcerting." Even with the 5% post-earnings pullback, Colgate shares are still not cheap, Nicholson tells investors in a research note. She lowered her price target for the shares to $70 from $76. 2. Air Products (APD) downgraded to Neutral from Outperform at Baird with analyst David Manthey saying he believes the catalyst that led to identifiable margin improvement last quarter may have substantially played out and the company is now more exposed to sluggish economic trends that have underpinned his cautious thinking on Praxair (PX). Manthey lowered his price target to $140 from $146 on Air Products shares. 3. Barclays (BCS) downgraded to Sell from Hold at Berenberg with analyst Peter Richardson citing valuation and high investment banking expectations reflected in shares. 4. Symantec (SYMC) reinstated with a Neutral from Buy at Citi with analyst Walter Pritchard downgrading Symantec (SYMC) to Neutral from Buy after reinstating coverage of the name. The analyst sees "weaker strategic merit" in the company's LifeLock (LOCK) acquisition relative to the Blue Coat deal. He also believes success is being priced in with investors looking for $2.00-plus in earnings power. Pritchard raised his price target for Symantec shares to $29 from $26.50. 5. CONSOL (CNX) downgraded to Hold from Buy at SunTrust. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MYL Mylan
$39.21

0.16 (0.41%)

06/12/17
SBSH
06/12/17
NO CHANGE
Target $38
SBSH
Buy
Citi says CRL for Coherus not worst case scenario
Citi analyst Mohit Bansal says Coherus Biosciences' (CHRS) complete response letter for its biosimilar version of Neulasta, while "clearly a negative outcome," is not the worst case scenario since the FDA did not ask for another study. The analyst sees a one year delay, which impacts his discounted free cash flow model by $5 per share. Coherus in premarket trading is down 30%, or $6.25, to $14.40. A one year delay would mean Coherus' CHS-1701 could still be on markets at the same time as competition from Mylan (MYL) and ahead of Sandoz's approval in 2019, Bansal tells investors in a research note. The analyst has a Buy rating on Coherus with a $38 price target.
06/21/17
WELS
06/21/17
NO CHANGE
WELS
Market Perform
Wells wouldn't be surprised to see greater scrutiny on Mylan coal tax credits
After a new report from Reuters questioned the way in which Mylan uses its ownership of coal processing plants to keep its taxes low, Wells Fargo analyst David Maris said this topic has interested him for some time but his questions to management on the issue were not answered. Maris, who said he would not be surprised to see greater public scrutiny on this issue after the report, keeps a Market Perform rating on Mylan shares.
06/16/17
CANT
06/16/17
INITIATION
Target $41
CANT
Neutral
Mylan initiated with a Neutral at Cantor
Cantor Fitzgerald analyst Louise Chen started Mylan with a Neutral rating and $41 price target.
05/31/17
WELS
05/31/17
NO CHANGE
WELS
Market Perform
Pension fund campaign a short-term negative for Mylan, says Wells Fargo
Wells Fargo analyst David Maris believes the campaign by four major pension funds to oppose the re-election of six directors is short-term negative for Mylan but has the potential to be a longer term positive. The campaign may pose a distraction to management, but if successful, it could address some governance concerns regarding compensation and performance at the company, Maris tells investors in a research note. The analyst has a Market Perform rating on Mylan shares.

TODAY'S FREE FLY STORIES

WAC

Walter Investment

$0.51

-0.0056 (-1.09%)

10:24
10/21/17
10/21
10:24
10/21/17
10:24
Hot Stocks
Walter Investment reaches agreement on financial restructuring »

Walter Investment has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMST

TimkenSteel

$17.57

0.19 (1.09%)

10:18
10/21/17
10/21
10:18
10/21/17
10:18
Hot Stocks
Tentative agreement between TimkenSteel, United Steelworkers voted down »

TimkenSteel employees who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

AGEN

Agenus

$4.33

-0.14 (-3.13%)

, GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

10:15
10/21/17
10/21
10:15
10/21/17
10:15
Hot Stocks
FDA approves GlaxoSmithKline shingles vaccine with Agenus QS-21 Stimulon »

Agenus (AGEN) has…

AGEN

Agenus

$4.33

-0.14 (-3.13%)

GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Nov

MS

Morgan Stanley

$50.68

0.89 (1.79%)

10:06
10/21/17
10/21
10:06
10/21/17
10:06
Periodicals
Another 20% gain in Morgan Stanley stock likely, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

SSNLF

Samsung

10:02
10/21/17
10/21
10:02
10/21/17
10:02
Periodicals
Samsung has lots of upside driven by chips/screens, Barron's says »

Samsung stock is up 50%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 30

    Oct

DLAKY

Lufthansa

$30.28

0.2 (0.66%)

09:56
10/21/17
10/21
09:56
10/21/17
09:56
Periodicals
Lufthansa has more room to climb, Barron's says »

Amid competitor's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$59.90

0.12 (0.20%)

, DAL

Delta Air Lines

$53.27

1 (1.91%)

09:51
10/21/17
10/21
09:51
10/21/17
09:51
Periodicals
Market pounds United, sees American/Delta as possibly safe bets, Barron's says »

United Continental's…

UAL

United Continental

$59.90

0.12 (0.20%)

DAL

Delta Air Lines

$53.27

1 (1.91%)

AAL

American Airlines

$51.93

0.42 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 26

    Oct

  • 01

    Nov

CZR

Caesars

$12.20

0.15 (1.24%)

09:45
10/21/17
10/21
09:45
10/21/17
09:45
Periodicals
Caesars looks ready to grow again, Barron's says »

After a disastrous 2008…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 08

    Nov

DWDP

DowDuPont

$71.18

0.29 (0.41%)

09:40
10/21/17
10/21
09:40
10/21/17
09:40
Periodicals
DowDuPont shares likely to return as much as 30% over next year, Barron's says »

If DowDuPont can cut $3B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COH

Coach

$40.35

0.88 (2.23%)

09:29
10/21/17
10/21
09:29
10/21/17
09:29
Periodicals
Coach shares look undervalued, could rise nearly 30%, Barron's says »

Coach, which has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$96.50

1.8 (1.90%)

, MOH

Molina Healthcare

$64.40

0.76 (1.19%)

09:24
10/21/17
10/21
09:24
10/21/17
09:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

CNC

Centene

$96.50

1.8 (1.90%)

MOH

Molina Healthcare

$64.40

0.76 (1.19%)

CI

Cigna

$191.42

3.2 (1.70%)

ANTM

Anthem

$194.69

1.49 (0.77%)

AET

Aetna

$160.84

3.2 (2.03%)

HNT

Health Net

HUM

Humana

$245.81

3.12 (1.29%)

UNH

UnitedHealth

$207.49

4.24 (2.09%)

WCG

WellCare

$180.52

3.28 (1.85%)

CYH

Community Health

$6.44

0.24 (3.87%)

HCA

HCA Healthcare

$81.05

1.26 (1.58%)

LPNT

LifePoint

$58.35

0.5 (0.86%)

THC

Tenet

$14.66

1.31 (9.81%)

UHS

Universal Health

$112.85

2.31 (2.09%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

MSFT

Microsoft

$78.81

0.9 (1.16%)

FB

Facebook

$174.98

0.42 (0.24%)

INTC

Intel

$40.43

0.34 (0.85%)

IBM

IBM

$162.07

1.17 (0.73%)

MAR

Marriott

$115.02

-0.18 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 26

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 02

    Nov

  • 02

    Nov

  • 03

    Nov

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 08

    Nov

  • 15

    Nov

  • 15

    Nov

  • 29

    Nov

  • 30

    Nov

  • 18

    Mar

ETFC

E-Trade

$43.20

-0.49 (-1.12%)

08:55
10/21/17
10/21
08:55
10/21/17
08:55
Conference/Events
E-Trade to hold an education day »

Chicago Education Day is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

08:45
10/21/17
10/21
08:45
10/21/17
08:45
General news
Breaking General news story  »

New York Federal Reserve…

FB

Facebook

$174.98

0.42 (0.24%)

, AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

08:25
10/21/17
10/21
08:25
10/21/17
08:25
Periodicals
Regulators inquiries fuel speculation about big tech breakup, Barron's says »

Facebook (FB), Amazon…

FB

Facebook

$174.98

0.42 (0.24%)

AMZN

Amazon.com

$982.91

-3.7 (-0.38%)

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 26

    Oct

  • 26

    Oct

  • 01

    Nov

  • 08

    Nov

  • 15

    Nov

  • 29

    Nov

  • 18

    Mar

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

07:58
10/21/17
10/21
07:58
10/21/17
07:58
Hot Stocks
DBV believes FDA suggested continue moving forward with Viaskin »

DBV Technologies (DBVT)…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

04:55
10/21/17
10/21
04:55
10/21/17
04:55
General news
Breaking General news story  »

New York Federal Reserve…

ETFC

E-Trade

$43.20

-0.49 (-1.12%)

04:55
10/21/17
10/21
04:55
10/21/17
04:55
Conference/Events
E-Trade to hold an education day »

Chicago Education Day is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.